Cellectar Biosciences, Inc. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Cellectar Biosciences, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2026-06-30 was $1.38M.
- Cellectar Biosciences, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2024-03-31 was $31.76M, a 1058611433.33% increase year-over-year.
- Cellectar Biosciences, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2023-03-31 was $3.00.
- Cellectar Biosciences, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2021-12-31 was $0.00.
- Cellectar Biosciences, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2023 was $13.24M.
- Cellectar Biosciences, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2021 was $18.65M.
- Cellectar Biosciences, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2019 was $1.38M, a 68.82% decline from fiscal 2018.
- Cellectar Biosciences, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2018 was $4.42M.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2026-06-30 | $1.38M 10-Q · filed 2026-08-13 | |
| 2024-03-31 | $31.76M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $13.24M 10-K · filed 2024-03-27 | |
| 2023-03-31 | $3.00 10-Q · filed 2023-11-13 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $18.65M 10-K · filed 2023-03-09 |
| 2021-09-30 | $7.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | |
| 2021-06-30 | $3.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | |
| 2021-03-31 | $8.29M 10-Q · filed 2022-05-10 | |
| 2020-09-30 | $31.71K 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $14.00 10-Q · filed 2020-11-09 | |
| 2019-12-31 | $1.38M 10-K · filed 2021-03-02 | |
| 2019-06-30 | $0.00 10-Q · filed 2019-11-12 | |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-07 | |
| 2018-12-31 | $4.42M 10-K · filed 2020-03-09 | |
| 2018-09-30 | $0.00 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $0.00 10-Q · filed 2019-11-12 | |
| 2018-03-31 | $0.00 10-Q · filed 2019-11-12 | |
| 2017-12-31 | $0.00 10-K · filed 2019-02-26 | |
| 2016-12-31 | $0.00 10-K · filed 2018-03-21 | |
| 2011-12-31 | $3.18M 10-K · filed 2014-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |